OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
9
Results
Show all
Save search
Copy query
Show results for
Unknown
(9)
Publication Date
Release Date
2025
(2)
2020
(2)
2021
(1)
2019
(1)
2017
(1)
2011
(1)
2008
(1)
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
Genetic contributions to pain: a review of findings in humans.
Not available
S-EPMC2667226
|
biostudies-literature
Cite
A protocol for a randomized controlled trial of photobiomodulation for management of temporomandibular disorder pain in Adults.
Not available
S-EPMC12702193
|
biostudies-literature
Cite
Effect of comorbid migraine on propranolol efficacy for painful TMD in a randomized controlled trial.
Not available
S-EPMC8166404
|
biostudies-literature
Cite
Efficacy and safety of propranolol for treatment of temporomandibular disorder pain: a randomized, placebo-controlled clinical trial.
Not available
S-EPMC7390887
|
biostudies-literature
Cite
Clinical findings and pain symptoms as potential risk factors for chronic TMD: descriptive data and empirically identified domains from the OPPERA case-control study.
Not available
S-EPMC3443556
|
biostudies-literature
Cite
GWAS Identifies New Loci for Painful Temporomandibular Disorder: Hispanic Community Health Study/Study of Latinos.
Not available
S-EPMC5298397
|
biostudies-literature
Cite
Oropouche Virus Infects, Persists and Induces IFN Response in Human Peripheral Blood Mononuclear Cells as Identified by RNA PrimeFlow™ and qRT-PCR Assays.
Not available
S-EPMC7411765
|
biostudies-literature
Cite
Genome-wide association reveals contribution of MRAS to painful temporomandibular disorder in males.
Not available
S-EPMC6377338
|
biostudies-literature
Cite
A standardized, open-source, portable model for noninvasive joint injury in mice.
Not available
S-EPMC12666826
|
biostudies-literature
Cite
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets